Navellier & Associates Inc. Invests $484,000 in Guardant Health, Inc. $GH

Navellier & Associates Inc. acquired a new stake in Guardant Health, Inc. (NASDAQ:GH) during the 3rd quarter, Holdings Channel.com reports. The firm acquired 7,754 shares of the company’s stock, valued at approximately $484,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. IFP Advisors Inc grew its holdings in Guardant Health by 120.1% during the 2nd quarter. IFP Advisors Inc now owns 612 shares of the company’s stock worth $33,000 after acquiring an additional 334 shares during the period. Allworth Financial LP boosted its position in shares of Guardant Health by 358.4% in the 2nd quarter. Allworth Financial LP now owns 706 shares of the company’s stock worth $37,000 after purchasing an additional 552 shares during the last quarter. Sound Income Strategies LLC bought a new stake in Guardant Health in the third quarter valued at about $38,000. FNY Investment Advisers LLC acquired a new position in shares of Guardant Health during the 2nd quarter worth about $62,000. Finally, Smartleaf Asset Management LLC grew its position in shares of Guardant Health by 162.2% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,096 shares of the company’s stock worth $68,000 after buying an additional 678 shares during the period. 92.60% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research firms recently weighed in on GH. Evercore set a $105.00 price objective on shares of Guardant Health and gave the stock an “in-line” rating in a research note on Monday, January 5th. Barclays increased their target price on shares of Guardant Health from $85.00 to $120.00 and gave the stock an “overweight” rating in a report on Monday, December 15th. Citigroup lifted their price target on shares of Guardant Health from $100.00 to $135.00 and gave the stock a “buy” rating in a research report on Thursday, December 11th. Mizuho set a $135.00 price objective on shares of Guardant Health in a research report on Friday, January 9th. Finally, JPMorgan Chase & Co. lifted their target price on Guardant Health from $90.00 to $120.00 and gave the stock an “overweight” rating in a report on Monday, December 15th. Twenty-one research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $106.86.

Guardant Health Stock Up 2.4%

Shares of GH stock opened at $107.58 on Thursday. Guardant Health, Inc. has a 12-month low of $34.88 and a 12-month high of $120.74. The firm has a fifty day moving average of $106.44 and a 200-day moving average of $83.20. The company has a market capitalization of $13.56 billion, a price-to-earnings ratio of -33.51 and a beta of 1.63.

Insider Transactions at Guardant Health

In other Guardant Health news, Director Medina Manuel Hidalgo sold 1,250 shares of the company’s stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $105.00, for a total transaction of $131,250.00. Following the completion of the transaction, the director owned 797 shares of the company’s stock, valued at $83,685. This represents a 61.06% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Amirali Talasaz sold 100,000 shares of the firm’s stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $105.05, for a total transaction of $10,505,000.00. Following the transaction, the chief executive officer directly owned 168,223 shares of the company’s stock, valued at $17,671,826.15. This represents a 37.28% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 434,627 shares of company stock worth $45,592,052. Corporate insiders own 6.10% of the company’s stock.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.